1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Merck’s Welireg Could Expand Into Broader Kidney Cancer Indication With Phase III Data

 
• By Alaric DeArment

The drug maker announced Phase III results for the HIF-2α inhibitor in renal cell carcinoma patients with disease progression following PD-1/PD-L1 and anti-VEGF therapy.

Merck announced results for Welireg in renal cell carcinoma after checkpoint inhibitor and anti-VEGF treatment • Source: Shutterstock

Merck & Co., Inc. stands to move the hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor Welireg (belzutifan) beyond its current indication of cancers associated with a rare genetic disorder, with results of a Phase III study showing it is effective in treating at least one of those cancers in a broader, heavily pretreated population as well.

Without disclosing data, the New Jersey-based drug maker announced results from the LITESPARK-005 trial comparing Welireg against everolimus in patients with advanced renal cell carcinoma (RCC) whose disease had progressed...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.